MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Public ClinicalTrials.gov record NCT05735717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Study identification
- NCT ID
- NCT05735717
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Enrollment
- 70 participants
Conditions and interventions
Conditions
- AML
- Acute Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- CBL Gene Mutation
- CNS Leukemia
- Chromosome Abnormality
- Cytogenetic Abnormality
- Fetal Hemoglobin
- Hematologic Malignancy
- High Grade Non-Hodgkin's Lymphoma, Adult
- Intrachromosomal Amplification of Chromosome 21
- Juvenile Myelomonocytic Leukemia
- Lymphoblastic Lymphoma
- Minimal Residual Disease
- Monosomy 7
- Myelodysplasia
- N-RAS Gene Amplification
- NF1 Mutation
- Neurofibromatosis 1
- PTPN11 Gene Mutation
- Remission
- Somatic Mutation
- TP53
Interventions
- Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Biological
- Busulfan Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- Levetiracetam Drug
- Melphalan Drug
- Rituximab Drug
- Thymoglobulin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- Up to 60 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 10, 2023
- Primary completion
- Nov 29, 2027
- Completion
- Nov 29, 2030
- Last update posted
- Apr 5, 2026
2023 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | 55455 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05735717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05735717 live on ClinicalTrials.gov.